Completed PHASE2 INTERVENTIONAL 1-arm NCT00888615

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: GOG Foundation

Conditions Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Tumor Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Interventions Elesclomol Sodium Paclitaxel

Updated 14 times since 2017 Last updated: Sep 28, 2021 Started: Dec 13, 2010 Primary completion: Sep 1, 2011 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fallopian Tube Clear Cell Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma and is currently completed. GOG Foundation leads this study, which shows 14 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Nov 2021 [monthly]

Completed PHASE2

▶ Show 9 earlier versions

Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Oct 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE2
Apr 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting
May 2017 — Jun 2017 [monthly]

Unknown Status PHASE2
Feb 2017 — May 2017 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GOG Foundation
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Akron, United States , Ames, United States , Ann Arbor, United States , Asheboro, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Baton Rouge, United States , Belpre, United States and 104 more locations